A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Serum proteomics of mother-infant dyads carrying HLA-conferred type 1 diabetes risk
Tekijät: Bhosale, Santosh D.; Moulder, Robert; Suomi, Tomi; Ruohtula, Terhi; Honkanen, Jarno; Virtanen, Suvi M.; Ilonen, Jorma; Elo, Laura L.; Knip, Mikael; Lahesmaa, Riitta
Kustantaja: Cell Press
Julkaisuvuosi: 2024
Journal: iScience
Tietokannassa oleva lehden nimi: iScience
Artikkelin numero: 110048
Vuosikerta: 27
Numero: 6
ISSN: 2589-0042
eISSN: 2589-0042
DOI: https://doi.org/10.1016/j.isci.2024.110048
Verkko-osoite: https://doi.org/10.1016/j.isci.2024.110048
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/404755571
In-utero and dietary factors make important contributions towards health and development in early childhood. In this respect, serum proteomics of maturing infants can provide insights into studies of childhood diseases, which together with perinatal proteomes could reveal further biological perspectives. Accordingly, to determine differences between feeding groups and changes in infancy, serum proteomics analyses of mother-infant dyads with HLA-conferred susceptibility to type 1 diabetes (n = 22), weaned to either an extensively hydrolyzed or regular cow’s milk formula, were made. The LC-MS/MS analyses included samples from the beginning of third trimester, the time of delivery, 3 months postpartum, cord blood and samples from the infants at 3, 6, 9 and 12 months. Correlations between ranked protein intensities were detected within the dyads, together with perinatal and age-related changes. Comparison with intestinal permeability data revealed a number of significant correlations, which could merit further consideration in this context.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
R.L. received funding from the Academy of Finland (grants 292335, 294337, 319280, 31444, 319280, 329277, and 331790), Business Finland and by grants from the JDRF, Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation, Finnish Diabetes Foundation, and the Finnish Cancer Foundation. L.E. reports grants from the European Research Council ERC (677943), Academy of Finland (296801, 310561, 314443, 329278, 335434, and 335611), and Sigrid Jusélius Foundation during the conduct of the study. R.L. and M.K. were supported by the Academy of Finland, AoF, Centre of Excellence in Molecular Systems Immunology and Physiology Research (2012–2017, grants 250114 and 292482). M.K. also received support from the Sigrid Jusélius Foundation, Helsinki University Hospital Research Funds and the Liv and Hälsa Fund.
